Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of PF-06480605 (Afimkibart) in Healthy Japanese Adults
NCT04269538Phase 1Completed
- Sponsor
- Telavant
- Start
- Feb 2020
- Primary completion
- Nov 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of afimkibart in ulcerative colitis (UC) and Crohn's disease (2 arms), sponsored by Telavant. Primary endpoints: Incidence of treatment related adverse events, Incidence, severity and causal relationship of treatment emergent adverse events (TEAEs) and withdrawals due to TEAEs and 3 more. Started Feb 2020; status: completed.
02
Drugs
afimkibart
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT04269538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04269538.